Phase II Trial of Single Agent Ofatumumab in Relapsed / Refractoy Mantle Cell Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 01 Jul 2015
At a glance
- Drugs Ofatumumab (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 17 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
- 20 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
- 04 Dec 2011 United Kingdom Clinical Research Network reports accrual to date changed from 32 to 35%.